Potential therapeutic effects and pharmac... - Cure Parkinson's

Cure Parkinson's

25,525 members26,845 posts

Potential therapeutic effects and pharmacological evidence of sinomenine in central nervous system disorders

Sydney75 profile image
9 Replies

Published online 2022 Sep 16, I realize it is a rat study, but it is sinomenine is used in Traditional Chinese Medicine.

Pharmacological effects of sinomenine in Parkinson’s disease

PD is a common neurodegenerative disorder characterized by progressive degeneration of dopaminergic neurons in the substantia nigra pars compacta and subsequent depletion of an important neurotransmitter in the striatum that can negatively control motor skills—dopamine (Nemade et al., 2021). Numerous therapeutic methods are available in the clinic, including drug and non-drug treatments, to treat PD. However, considering the low efficacy of treatment and severe side effects, the development of new drugs is always a hot topic for PD research. Administration of sinomenine (i.p., 20 mg/kg, 5 days before treatment with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and for another 4 days) can suppress the MPTP-induced decline in rotarod time, pounds for grip strength, and forepaw stride length in mice, which was accompanied by an increase in tyrosine hydroxylase (TH)-positive cells in the substantia nigra pars compacta (Bao et al., 2022) (Table 2), suggesting that sinomenine administration improves motor skills in mice with PD by promoting the survival of dopaminergic neurons.

Autophagy is a general biological process that mediates the pathogenesis of PD (Sepúlveda et al., 2022). Promoting autophagy is considered a potential strategy for the treatment of PD. Administration of sinomenine can suppress the MPTP-induced decrease in Beclin-1 and LC3-II/LC3-I ratio, as well as the MPTP-induced increase in p62 in the substantia nigra pars compacta of the mouse brain, by inhibiting the protein kinase B (Akt)-mammalian target of rapamycin (mTOR) signaling (Figure 4; Table 2) (Bao et al., 2022), suggesting that triggering autophagy may mediate the action of sinomenine against PD. This hypothesis is supported by the finding that MHY1485, a specific activator of the Akt-mTOR signaling pathway that affects autophagy, further impairs the motor abilities of PD mice and attenuates the beneficial effect of sinomenine on the motor abilities of PD mice by promoting the loss of dopaminergic neurons (Bao et al., 2022).

An external file that holds a picture, illustration, etc.

Object name is fphar-13-1015035-g004.jpg

FIGURE 4

Effects and mechanisms of sinomenine in pathological conditions resembling PD. Sinomenine can inhibit MPTP-induced dephosphorylation of Akt and mTOR, thereby promoting the process of autophagy by increasing the expression of Beclin-1, increasing the LC3-II/LC3-I ratio, and reducing the accumulation of p62 Bao et al. (2022). Sinomenine may also suppress neuroinflammation triggered by MPP+ or LPS, thereby increasing dopamine uptake Qian et al. (2007).

Another mechanism for the anti-PD effect of sinomenine may be related to the inhibition of neuroinflammation, because pre-incubation with sinomenine (10−6, 10−5, 10−14, 10−13 M) can simultaneously prevent the LPS-induced decrease in the ability of midbrain neuron-enriched cultures to take up dopamine and the LPS-induced decrease in TH-positive neurons in midbrain neuron-enriched cultures (Figure 4; Table 2) (Qian et al., 2007). Mechanistic studies showed that the neuroprotective effect of sinomenine in the above model may be highly related to the attenuating effect of sinomenine on the LPS-induced production of TNF-α, prostaglandin E2 (PGE2), and NO, as well as on the expression of iNOS in rat microglia-enriched cultures (Figure 4; Table 2) (Qian et al., 2007). This hypothesis is also supported by the finding that incubation with sinomenine prevented the MPP+-induced decrease in dopamine uptake in primary mesencephalic neuron-glia cultures by microglia: Sinomenine showed no effect on the toxic effects of 1-methyl-4-phenylpyridiniumion (MPP+) in primary mesencephalic neuron cultures, which was restored when the neuron-enriched cultures were reconstituted with purified microglia but not astrocytes (Qian et al., 2007) (Table 2). Thus, it is possible that sinomenine does not directly protect neurons from MPP+-mediated toxicity, but that targeting microglia is a crucial process. However, it is worth noting that although microglia are known to mediate the pathogenesis of PD through neuroinflammation, sinomenine did not suppress MPP+-induced production of TNF-α and NO in the presence of microglia, but suppressed MPP+-induced production of superoxide in rat mesencephalic neuron-glia cultures, suggesting that inhibition of superoxide-associated oxidative stress, but not neuroinflammation, may mediate the anti-neurotoxic effect of sinomenine (Qian et al., 2007).

I think the best way to incorporate TCM is to see a TCM practicioner.

-Syd

Written by
Sydney75 profile image
Sydney75
To view profiles and participate in discussions please or .
Read more about...
9 Replies
park_bear profile image
park_bear

Hi Sydney,

This is not a personal criticism - this is a criticism of a particular type of research. Why animal models have a bad reputation here:

"Administration of sinomenine (i.p., 20 mg/kg, 5 days before treatment with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and for another 4 days) can suppress the MPTP-induced decline in rotarod time, pounds for grip strength, and forepaw stride length in mice, which was accompanied by an increase in tyrosine hydroxylase (TH)-positive cells in the substantia nigra pars compacta (Bao et al., 2022) (Table 2),[NOT!] suggesting that sinomenine administration improves motor skills in mice with PD by promoting the survival of dopaminergic neurons." [emphases added]

Fail because pretreatment never allows Parkinson's to develop. So not a valid test. Further discussion here:

healthunlocked.com/cure-par...

Sydney75 profile image
Sydney75 in reply to park_bear

Thanks! You understand research models better than me. I an actually researching TCM for pain.

Ramuu profile image
Ramuu

Hi Sydney 75, I am suffering from PD for 15 years. You have mentioned about treatment for PD by AUTO PHAGY . HAS anyone has cured PD by FASTING ?? CA N YOU PLAESE give me references of such patients ??

Sydney75 profile image
Sydney75 in reply to Ramuu

For idiopathic PD I think theie is a direct correlation to our gut which is our "2nd brain". The only thing proven to slow progression of PD is cardio exercise.

Ramuu profile image
Ramuu in reply to Sydney75

HI SYDNEY 75 , YOUR REPLY DOES NOT ANSWER MY QUESTION. YOU HAVE. YOU HAVE POSTED THAT TREATMENT OF PD BY AUTO PHAGY . I HAVE ASKED YOU , DO YOU HAVE ANY REFRENCES ,PATIENT S WHO HAVE CURED BY FASTING. FOR THIS U H AVE ANSERWED. PD DIRECT RELAATION TO BRAIN !!!

Reetpetitio profile image
Reetpetitio

I couldn't agree more - ideally, to see a Chinese Medical Doctor. Chinese medicine has a couple of thousands years on Western medicine and has an infinitely deeper understanding of chronic disease and how to rebalance the body. They have good success with Parkinsons and it's a little sad seeing Western medicine researchers focus on one very small component of the Chinese pharmacy in a presumed desire to create a patentable drug. Chinese medicine already knows what Western medicine is starting to realise, that PD is not one disease but an entire umbrella - and they treat those variants and expressions of imbalance, in a way Western medicine simply can't.

Note to self - book that first treatment with the Chinese Doctor!!

Ramuu profile image
Ramuu in reply to Reetpetitio

Hi Reetpetition, I understand imbalance of Body elements , as per AYURVEDA , all the chronic diseases are caused by IMBALANCE of KPAHA, PITHA and VATHA. which results i n BAD GUT , resulting in bad gut bacteria travel to BRAIN via GUT - BRAIN AXIS which causes most of the BRAIN DISDORDERS. TO, RESET THE GUT THERE ARE PUNCHA KARMA TREAT MENTS. I HAVE UNDERGONE THESE TREAT MENTS, INITIALLYN, IT ERAALY HELPE D ME T O OVERMCOME TREMORS, BALANCE AND FREEZING. BUT AS THE DISESAE PROGERESSED, TEHSE TREATBESMNTB DID NOT HELP ME MUCH , ,I THINK , THESE TRREATEMSNTS HAVE LIMIATIOMS..

Reetpetitio profile image
Reetpetitio in reply to Ramuu

That's interesting, thank you. In my mind, if I were to put myself into the care of an Ayurvedic physician, it would be a consistent approach of Panchakarma cleanses combined with diet and ayurvedic herbs throughout the year. Is that what you did, or was it more annual Panchakarma without herbs/support the rest of the time?

Ramuu profile image
Ramuu in reply to Ramuu

Hi Reetpetitio, I am still under the AYURVEDIC medicine , called KAPIKACHHU - INDIAN MUCANA, with 250ML of HOT WATER it will put me to ON conditon in 10 to 15 MINs. DOSAGE HAS TO BE TAKEN in EEMPTY STOMACH to work. I TAKE 3 d oses daily, of 1.5 SPOONS each doose i .e, about 11, 25 GRAMS . I Take KASHAYAM ( AN AYURVEDIC PREPARATION ) with AYURVEVDIC GHEE 15 ML in HOT WATER at 5.30 AM, which is belibeved to help the Kapikapi kachhu to reach the brain by crossing the BLOOD BRAIN BARRIER .I take first dose of KAPIKACHHU at 6.30 AM , which will put me to ON CONDITION qt 6.45 AM. I will take bath at 7.0.0 AM, , I will be in oN condition, i will take 2nd doose of KPAIKACHU at 9.15 AM, ,i will have B/F at 9,45 AM, I will have 3rd dose at 12,.30PM and ahve the LLUNCH at 1.00PM. THis medicine become weak 2.30 PM, As the medicien bceomes weak, I will get terrible tremors. AS this emdiciens workss only in empty stomac h,, i will suffer with him high intensity tremors from 2.45 PM to 4.00pm , there after I will continue to s uffer high intensity RLS of body parts till next day morning7.00 A

You may also like...

Add Idebenone Back to my Stack?

shift of microglia from the M1 to M2 phenotype in LPS-activated BV2 cells and the MPTP induced PD...

The Endotoxin Hypothesis of Parkinson's Disease

brainstem nuclei and loss of dopaminergic neurons in the substantia nigra, and manifesting in the...

Another potential PD therapeutic drug?

Tauroursodeoxycholic acid: a potential therapeutic tool in neurodegenerative diseases 2022 (TUDCA)

indicate that TUDCA exerts its effects not only by regulating and inhibiting the apoptotic cascade,...

Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline